Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.63 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.59 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 7/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29206616 | 0.98 | EPHX1 (0.67) | EPHX1PAOXGNAI3GNAO1GNAI1 | |
| SCHEMBL13037020 | 0.98 | EPHX1 (0.67) | EPHX1PAOXGNAI3GNAO1GNAI1 | |
| SCHEMBL6995766 | 0.93 | — | — | |
| SCHEMBL16326645 | 0.92 | EPHX1 (0.55) | EPHX1PAOXMAOAMAOBMEN1 | |
| Hydrochloric Acid SCHEMBL31656480 | 0.91 | EPHX1 (0.57) | EPHX1PAOXACHETDP1 | |
| SCHEMBL14041194 | 0.90 | EPHX1 (0.57) | EPHX1PAOXMAOAMAOBMEN1 | |
| SCHEMBL7252127 | 0.88 | EPHX1 (0.77) | EPHX1ACHETDP1KDM4EMAPK1 | |
| SCHEMBL7788927 | 0.85 | EPHX1 (0.82) | EPHX1ACHETDP1KDM4EMAPK1 | |
| SCHEMBL7788569 | 0.85 | EPHX1 (0.82) | EPHX1ACHETDP1KDM4EMAPK1 | |
| SCHEMBL7788937 | 0.85 | EPHX1 (0.82) | EPHX1ACHETDP1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928504-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2931316-B1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20180186918-A1 | MULTI-FUNCTIONAL CARBAMATE HAVING SOFT-SEGMENTS, POLYISOCYANATE OBTAINED VIA SUBSEQUENT NON-PHOSGENE SYNTHESIS METHODS, URETHANE PREPOLYMER AND ELASTOMERIC URETHANE HAVING SOFT-SEGMENTS DERIVED THEREFROM, AND PREPARATION METHOD THEREOF | GREAT EASTERN RESINS INDUSTRIAL CO., LTD. (TW) | 2018-07-05 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3228325-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | Mersana Therapeutics, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| EP-2717916-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20160220696-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| WO-2014008375-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| WO-2012171020-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090099061-A1 | SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS | CARDAX PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2008118862-A1 | CAROTENOID ANALOGS AND DERIVATIVES FOR THE PREVENTION OF PLATELET AGGREGATION | CARDAX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | EPHX1 4311/4885PAOX 856/4885GNAI3 3041/4885 |
| US-20180186918-A1 | MULTI-FUNCTIONAL CARBAMATE HAVING SOFT-SEGMENTS, POLYISOCYANATE OBTAINED VIA SUBSEQUENT NON-PHOSGENE SYNTHESIS METHODS, URETHANE PREPOLYMER AND ELASTOMERIC URETHANE HAVING SOFT-SEGMENTS DERIVED THEREFROM, AND PREPARATION METHOD THEREOF | PUF60, NOTUM, PFAS | EPHX1 3895/4885PAOX 1563/4885GNAI3 3845/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | EPHX1 4311/4885PAOX 856/4885GNAI3 3041/4885 |
| US-20160220696-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | EPHX1 4579/4885PAOX 1891/4885GNAI3 3685/4885 |
| US-20090099061-A1 | SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS | CAT, HBZ, POLL | EPHX1 2995/4885PAOX 112/4885GNAI3 4613/4885 |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MALT1, ALG1, PRMT3 | EPHX1 3806/4885PAOX 2650/4885GNAI3 3870/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | EPHX1 1924/4885PAOX 2272/4885GNAI3 1338/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | EPHX1 4382/4885PAOX 852/4885GNAI3 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.